SOCIAL EFFECTS OF “NEGLECTED TROPICAL DISEASES” (on the example of “antivenom crisis”)

The article is devoted to the crisis situation in global health connected with the problem of neglected tropical diseases and its social effects. Negative social consequences of this group of diseases, include increase in mortality and disability, are most often due to the fact that their importance for modern society is considered in the context of their epidemiological potential. As a result, diseases that are prevalent in certain regions but are not of an infectious nature can be displaced to the periphery of the health agenda. This fact leads to appropriate modifications in the behavior of international companies that form the global market for biopharmaceuticals. As the example we take the problem of snake bites, which was on June 9, 2017 included by the World Health Organization in the list of “neglected tropical diseases”. Since the beginning of the 2000s, in various tropical and subtropical countries, there have been situations called “snake bite crisis” or “serum crisis”. Increasing the cost of the main means of therapy for snake bites – specific immunoglobulins (antiserum or antivenins) leads to the fact that the health systems of developing countries are unable to purchase it, and producers lose interest in developing this kind of biopharmaceutical products. Since the early 1980s, several major producers of antivenins – Syntex, Behringwerke AG, Sanofi-Pasteur, Wyeth – have stopped production of them or have completely left the market. This resulted in a deficit of antivenins observed in several regions, which led to the destruction or distortion of the model of interaction between patients and medical structures, the revival of archaic practices that have become an alternative to modern techniques that have shown inefficiency due to the lack of a key component. It is concluded that a qualitative change in the situation is possible only as a result of the coordinated interaction of various groups of actors (representatives of the expert community, biopharmaceutical companies, national governments, health authorities and international organizations, including WHO).

1. “Esli ljudi ne budut ponimat’, chto my delaem, oni nikogda ne pridut v nashi kliniki” [“If people do not understand what we are doing, they will never come to our clinics”]. URL: https://ru.msf.org/ru/efiopiya-esli-lyudi-ne-budut-ponimatchtomy-delaem-oni-nikogda-ne-pridut-v-nashi-kliniki (accessed: 19.11.2017) (in Russian).

2. About GSI. URL: http://www.snakebiteinitiative.org/?page_id=567 (accessed: 19.11.2017).

3. Alagón A. Anticuerpos seguros y eficaces: la revolución de los nuevos antivenenos // Revista de la Universidad Nacional Autónoma de México. 2002. N 617. URL: http://www.revistadelauniversidad.unam.mx/ojs_rum/index.php/rum/article/view/15507/16745/ (accessed: 18.11.2017).

4. Arnold C. Vipers, mambas and taipans: the escalating health crisis over snakebites // Nature. 2016. Sept. N 537. P. 26–28. Doi:10.1038/537026a.

5. Bochner R. Paths to the discovery of antivenom serotherapy in France // Journal of Venomous Animals and Toxins including Tropical Diseases. 2016. Vol. 22. P. 20. URL: https://dx.doi.org/10.1186/s40409-016-0074-7

6. Bochner R., Struchiner C.J. Acidentes por animais peçonhentos e sistemas nacionais de informação // Cad. Saúde Pública. 2002. Vol. 18. N 3. P. 735–746. URL: http://dx.doi.org/10.1590/S0102-311X2002000300017

7. Boyer L.V. Commentary: on 1000-fold pharmaceutical price markups, and why drugs cost more in the US than in Mexico // American Journal of Medicine. Vol. 128. N 12. Doi:10.1016/j.amjmed.2015.08.007.

8. Brazil V. A defesa contra o ophidismo. SãoPaulo, 1911. URL: http://dx.doi.org/10.5962/bhl.title.70080

9. Brown N.I. Consequences of neglect: analysis of the Sub-Saharan African snake antivenom market and the global context // PLOS Neglected Tropical Diseases. 2012. Vol. 6. N 6. Doi:10.1371/journal.pntd.0001670.

10. Calvete J.J., Sanz L., Angulo Y. et al. Venoms, venomics, antivenomics // FEBS Letters. 2009. Vol. 583. Iss. 11. P. 1736–1743. Doi: 10.1016/j.febslet.2009.03.029.

11. Charles Campbell Toxinology Centre. URL: http://www.cctcpng.org (accessed: 14.11.2017).

12. Chippaux J.-P. The development and use of immunotherapy in Africa // Toxicon. 1998. Vol. 36. Iss. 11. P. 1503–1506.

13. Chippaux J.-P. Snakebite envenomation turns again into a neglected tropical disease! // The Journal of Venomous Animals and Toxins Including Tropical Diseases. 2017. Vol. 23. P. 38. Doi:10.1186/s40409-017-0127-6.

14. Chippaux J.-P., Diédhiou I., Stock R. Étude de l’action de la pierre noire sur l’envenimation expérimentale // Cahiers d’études et de recherches francophones. Santé. 2007. Vol. 17. N 3. P. 127–131. Doi:10.1684/san.2007.0076.

15. GDP (current US$). World Development Indicators. World Bank. URL: Rhttps://data.worldbank.org/indicator/NY.GDP.MKTP.CD?year_high_desc=true (accessed: 14.11.2017).

16. Gomes A.C.V. “Too Good to be true”: the controversy over the use of permanganate of potash as an antidote to snake poison and the circulation of Bra118 zilian physiology in the nineteenth century // Bulletin of the History of Medicine. Vol. 86. N 2. P. 153–177. Doi: 10.1353/bhm.2012.0039

17. Guidolin F.R., Caricati C.P., Marcelino J.R. et al. Development of equine IgG antivenoms against major snake groups in Mozambique // PLOS Neglected Tropical Diseases. 2016. Vol. 10. N 1. URL: https://doi.org/10.1371/journal.pntd.0004325

18. Gutiérrez J.M., Burnouf T., Harrison R.A. et al. A multicomponent strategy to improve the availability of antivenom for treating snakebite envenoming // Bulletin of the World Health Organization. 2014. Vol. 92. P. 526–532. URL: http://www.who.int/bulletin/volumes/92/7/13-132431/en/ (accessed: 15.11.2017).

19. Habib A.G. Public health aspects of snakebite care in West Africa: perspectives from Nigeria // The Journal of Venomous Animals and Toxins Including Tropical Diseases. 2013. Vol. 19. P. 27. DOI: 10.1186/1678-9199-19-27.

20. Habib A.G., Lamorde M., Dalhat M.M. et al. Cost-effectiveness of antivenoms for snakebite envenoming in Nigeria // PLOS Neglected Tropical Diseases. 2015. Vol. 1. URL: https://doi.org/10.1371/journal.pntd.0003381/

21. Hamza M., Idris M.A., Maiyaki M.B., et al. Cost-effectiveness of antivenoms for snakebite envenoming in 16 countries in West Africa // PLoS Neglected Tropical Diseases. 2016. Vol. 10. N 3. DOI: 10.1371/journal.pntd.0004568.

22. Harrison R.A., Gutiérrez J.M. Priority actions and progress to substantially and sustainably reduce the mortality, morbidity and socioeconomic burden of Tropical Snakebite // Toxins. 2016. Vol. 8. N 12. P. 351. DOI: 10.3390/toxins8120351.

23. Harrison R.A., Hargreaves A., Wagstaff S.C. et al. Snake envenoming: a disease of poverty // PLOS Neglected Tropical Diseases. 2009. Vol. 3. N 12. DOI: 10.1371/journal.pntd.0000569.

24. Hawgood B.J. Doctor Albert Calmette 1863–1933: founder of antivenomous serotherapy and of antituberculous BCG vaccination // Toxicon. 1999. Vol. 37. N 9. P. 1241–1258. DOI: 10.1016/s0041-0101(99)00086-0.

25. http://mkb-10.com

26. http://www.toxinology.com/generic_static_files/cslavh_antivenom_taipan.html

27. http://www.who.int/classifications/icd/en/

28. Informacionnyj bjulleten’ VOZ [WHO Newsletter]. 2013. Fevr. N 373. URL: http://www.who.int/mediacentre/factsheets/fs373/ru/ (data obrashhenija: 15.11.2017) (in Russian).

29. Ipser Afrique antivenom [Supplementary Concept]. URL: https://www.ncbi.nlm.nih.gov/mesh/67059820 (accessed: 18.11.2017).

30. Kasturiratne A., Pathmeswaran A., Wickremasinghe A.R. et al. The socio-economic burden of snakebite in Sri Lanka // PLOS Neglected Tropical Diseases. 2017. Vol. 7. URL: https://doi.org/10.1371/journal.pntd.0005647

31. Kasturiratne A., Wickremasinghe A.R., de Silva N. et al. The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths // PLOS Medicine. 2008. Vol. 5. N 11. URL: http://doi.org/10.1371/journal.pmed.0050218

32. McGain F., Winkel K.D., Limbo A. et al. Snakebite mortality at Port Moresby General Hospital, Papua New Guinea, 1992–2001 // The Medical Journal of Australia. 2004. Vol. 181. N 11. P. 687–691.

33. Osipova N.G. Cocial’noe konstruirovanie obshhestvennogo zdorov’ja [Social construction of public health] // Vestnik Moskovskogo universiteta. Serija 18. Sociologija i politologija [Bulletin of Moscow University. Series 18. Sociology and Political Science]. 2016. T. 22. N 4. S. 119–141. DOI: 10.24290/10293736-2016-22-4-119-141 (in Russian).

34. Othong R., Sheikh S., Alruwaili N. et al. Exotic venomous snakebite drill // Clinical Toxicology. 2012. Vol. 50. Iss. 6. P. 490–496. DOI: http://dx.doi.org/10.3109/15563650.2012.690882

35. Perelygina O.V., Komarovskaja E.I. Sravnitel’nyj analiz trebovanij k kachestvu geterologichnyh syvorotochnyh preparatov v farmakopejah vedushhih stran – proizvoditelej lekarstvennyh sredstv [Comparative analysis of the requirements for the quality of heterologous serum preparations in pharmacopoeias of the leading countries manufacturers of medicines] // Biopreparaty. Profilaktika, diagnostika, lechenie [Biopreparations. Prevention, diagnosis, treatment]. 2017. N 1 (61). S. 32–40 (in Russian).

36. Potet J., Cohn J. A market failure case study: African snake antivenoms. URL: http://www.globe-network.org/sites/default/files/en/network/resource/3.jennifer-cohn-and-julien-potet-a-market-failure-case-study-snake-anti-venoms_.pdf/ (accessed: 18.11.2017).

37. Ramos-Cerrillo B., de Roodt A.R., Chippaux J.-P. et al. Characterization of a new polyvalent antivenom (Antivipmyn Africa) against African vipers and elapids // Toxicon. 2008. Vol. 52. N 8. P. 881–888. Doi: 10.1016/j.toxicon.2008.09.002.

38. Sanofi Pasteur’s information on Fav-Afrique®. URL: http://www.sanofipasteur.com/en/Documents/PDF/Fav-Afrique%20statement_11May2016_EN.pdf (accessed: 18.11.2017).

39. Schiermeier Q. Africa braced for snakebite crisis // Nature. 2015. Sept. N 525. P. 299. Doi:10.1038/525299a.

40. Simpson I.D., Norris R.L. Snake antivenom product guidelines in India: “the devil is in the details” // Wilderness Environ Med. 2007. Vol. 18. N 3. P. 163–168. DOI: 10.1580/07-WEME-ED-099R.1.

41. Stock R.P., Massougbodji A., Alagón A. et al. Bringing antivenoms to SubSaharan Africa // Nat. Biotechnol. 2007. Vol. 25. N 2. P. 173–177.

42. Theakston R.D.G., Warrell D.A. Crisis in snake antivenom supply for Africa // The Lancet. 2000. Vol. 356. P. 2104.

43. Vargas M., Segura A., Herrera M., et al. Preclinical Evaluation of Caprylic acid-fractionated IgG antivenom for the treatment of taipan (Oxyuranus scutellatus) envenoming in Papua New Guinea // PLOS Neglected Tropical Diseases. 2011. Vol. 5. N 5. DOI: 10.1371/journal.pntd.0001144.

44. Welton R.E., Liew D., Braitberg G. Incidence of fatal snake bite in Australia: a coronial based retrospective study (2000–2016) // Toxicon. 2017. Vol. 131. P. 11–15.

45. Williams D. Are Australian snakes the deadliest in the world? Not even close // The Conversation, CC BY-ND. 2016. 10 Jan. URL: https://theconversation.com/are-australian-snakes-the-deadliest-in-the-world-not-even-close-50963 (accessed: 16.11.2017).

46. Williams D., Gutiérrez J.-M., Harrison R. et al. The global snake bite initiative: an antidote for snake bite // Lancet. 2010. Vol. 375. P. 89–91.

47. Working to overcome the global impact of neglected tropical diseases. First WHO report on neglected tropical diseases. WHO/HTM/NTD/2010.1. URL: http://apps.who.int/iris/bitstream/10665/44440/1/9789241564090_eng.pdf (accessed: 15.11.2017).

48. Zabytye tropicheskie bolezni. Profilaktika, bor’ba i polnaja ili chastichnaja likvidacija. Doklad Sekretariata Vsemirnoj organizacii zdravoohranenija [Forgotten tropical diseases. Prevention, struggle and total or partial elimination. Report of the Secretariat of the World Health Organization]. URL: http://apps.who.int/gb/ebwha/pdf_files/EB132/B132_19-ru.pdf (data obrashhenija: 15.11.2017) (in Russian).